Glucose-dependent insulinotropic polypeptide: difference between revisions
Diff·revision 23 → 24·03:07, 10 Nov 2024
Difference between revision 23 and revision 24 of Glucose-dependent insulinotropic polypeptide. 4 lines changed; the page grew by 159 bytes.
| Revision 23 — 07:25, 30 Oct 2024 FiveOhThreeB (talk) add citation for the incidence figure 5,300 bytes +33 | Revision 24 — 03:07, 10 Nov 2024 Chromatokid (talk) attribute range as a review estimate per talk 5,459 bytes +159 | ||
|---|---|---|---|
| 11 | | Monoisotopic mass = ≈4,972 Da | 11 | | Monoisotopic mass = ≈4,972 Da |
| 12 | | Plasma half-life = 7 minutes | 12 | | Plasma half-life = 7 minutes |
| + | 13 | <!-- Receptor --> | |
| + | 14 | | Target = GIP receptor (GIPR) | |
| + | 15 | | Receptor family = Class B secretin-like GPCR | |
| + | 16 | | Principal coupling = G<sub>s</sub> → adenylyl cyclase | |
| 13 | }} | 17 | }} |
| 14 | {{hatnote|Formerly known as glucose-dependent insulinotropic peptide (GIP). For the GLP-1 arm of the incretin axis, see [[Glucagon-like peptide-1]]. For the receptor it acts on, see [[GLP-1 receptor agonist]] for clinical context.}} | 18 | {{hatnote|Formerly known as glucose-dependent insulinotropic peptide (GIP). For the GLP-1 arm of the incretin axis, see [[Glucagon-like peptide-1]]. For the receptor it acts on, see [[GLP-1 receptor agonist]] for clinical context.}} |